Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth B Gordon

Showing results (71-80 of 136) with videos related to

Pageof 14
Sort By:
Dermatology and Therapy|November 4, 2023
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative ReviewAndrew Blauvelt, Richard G Langley, Kenneth B Gordon, et al.
Clinical Therapeutics|November 18, 2005
Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experienceRichard G B Langley, Wayne P Carey, Elyse S Rafal, et al.
Dermatology and Therapy|August 23, 2024
Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation AnalysisApril W Armstrong, Peter Foley, Yan Liu, et al.
International Journal of Dermatology|May 17, 2006
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trialKim A Papp, Reni Bressinck, Scott Fretzin, et al.
Lancet (London, England)|May 20, 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Craig L Leonardi, Alexa B Kimball, Kim A Papp, et al.
The Journal of Dermatology|October 22, 2019
Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2Kristian Reich, Michael Song, Shu Li, et al.
Journal of the American Academy of Dermatology|May 14, 2010
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trialRichard G Langley, Steven R Feldman, Chenglong Han, et al.
The Journal of Dermatological Treatment|December 7, 2007
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasisDennis A Revicki, Mary Kaye Willian, Alan Menter, et al.
The New England Journal of Medicine|July 9, 2015
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque PsoriasisKenneth B Gordon, Kristina Callis Duffin, Robert Bissonnette, et al.
Lancet (London, England)|February 7, 2021
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialKenneth B Gordon, Peter Foley, James G Krueger, et al.
Pageof 14

Showing results (71-80 of 136) with videos related to

Sort By:
Pageof 14
Dermatology and Therapy|November 4, 2023
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative ReviewAndrew Blauvelt, Richard G Langley, Kenneth B Gordon, et al.
Clinical Therapeutics|November 18, 2005
Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experienceRichard G B Langley, Wayne P Carey, Elyse S Rafal, et al.
Dermatology and Therapy|August 23, 2024
Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation AnalysisApril W Armstrong, Peter Foley, Yan Liu, et al.
International Journal of Dermatology|May 17, 2006
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trialKim A Papp, Reni Bressinck, Scott Fretzin, et al.
Lancet (London, England)|May 20, 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Craig L Leonardi, Alexa B Kimball, Kim A Papp, et al.
The Journal of Dermatology|October 22, 2019
Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2Kristian Reich, Michael Song, Shu Li, et al.
Journal of the American Academy of Dermatology|May 14, 2010
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trialRichard G Langley, Steven R Feldman, Chenglong Han, et al.
The Journal of Dermatological Treatment|December 7, 2007
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasisDennis A Revicki, Mary Kaye Willian, Alan Menter, et al.
The New England Journal of Medicine|July 9, 2015
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque PsoriasisKenneth B Gordon, Kristina Callis Duffin, Robert Bissonnette, et al.
Lancet (London, England)|February 7, 2021
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialKenneth B Gordon, Peter Foley, James G Krueger, et al.
Pageof 14